Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/FCF ratio is N/A as of 2026-10-06T13:30:28.512Z.
Calculation as of: 2026-10-06T13:30:28.512Z.
Quote observation: 2026-10-06T13:30:00.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: ad057aee5ab633aed0c7ef60ea3d5b85ea99b1ff07310db4f6411376a188a91d
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/FCF RATIO
N/A
Market Cap
$876.90M
EV/FCF Ratio
N/A
TTM Avg
10.33x
3Y Avg
10.33x
5Y Avg
10.33x
Market Cap
$825.02M
EV/FCF Ratio
N/A
TTM Avg
402.12x
3Y Avg
246.51x
5Y Avg
209.59x
Market Cap
$791.64M
EV/FCF Ratio
N/A
TTM Avg
26.28x
3Y Avg
227.60x
5Y Avg
393.69x
| NAME | MARKET CAP | EV/FCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Alumis Inc. (ALMS) | $850.45M | N/A | N/A | N/A | N/A |
| Ardelyx, Inc. (ARDX)vs › | $837.43M | N/A | 4.50x | 4.50x | 4.50x |
| Beta Bionics, Inc. (BBNX)vs › | $850.75M | N/A | N/A | N/A | N/A |
| Jade Biosciences, Inc. (JBIO)vs › | $864.21M | N/A | N/A | N/A | N/A |
| Apnimed, Inc. (APMD)vs › | $873.72M | N/A | N/A | N/A | N/A |
| Monte Rosa Therapeutics, Inc. (GLUE)vs › | $876.90M | N/A | 10.33x | 10.33x | 10.33x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $825.02M | N/A | 402.12x | 246.51x | 209.59x |
| InMode Ltd. (INMD)vs › | $812.78M | 4.81x | 6.37x | 8.04x | 13.91x |
| Cytek Biosciences, Inc. (CTKB)vs › | $791.64M | N/A | 26.28x | 227.60x | 393.69x |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $903.97M | N/A | N/A | N/A | N/A |
EV/FCF
N/A
P/FCF
N/A
FCF Yield
N/A
Formula: EV/FCF = Enterprise Value / Free Cash Flow
EV/FCF vs P/FCF:
EV/FCF = Enterprise Value / Free Cash Flow (TTM)
Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
